Device beats drugs for atrial fib

A Johnson & Johnson unit released study data yesterday showing that its catheter-based system might be more effective than drugs are at resolving heart arrhythmias. The company's Biosense Webster unit is hoping to gain FDA approval to market the device for the treatment of atrial fibrillation, making it the first approved device to treat the condition. AtriCure , Boston Scientific, Medtronic and St. Jude Medical all have competing devices, but none have received FDA approval for the condition to date. Report

 

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.